Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...

The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.

From the practical wisdom of emphasising exercise to improve survival in colon cancer to the association of glucagon-like ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...